1.Yubi-Wakka Test for Sarcopenia Screening: Influence of Abdominal Obesity on Diagnostic Performance
Melissa Rose Berlin PIODENA-APORTADERA ; Sabrina LAU ; Cai Ning TAN ; Justin CHEW ; Jun Pei LIM ; Noor Hafizah ISMAIL ; Yew Yoong DING ; Wee Shiong LIM
Annals of Geriatric Medicine and Research 2025;29(1):138-141
2.Yubi-Wakka Test for Sarcopenia Screening: Influence of Abdominal Obesity on Diagnostic Performance
Melissa Rose Berlin PIODENA-APORTADERA ; Sabrina LAU ; Cai Ning TAN ; Justin CHEW ; Jun Pei LIM ; Noor Hafizah ISMAIL ; Yew Yoong DING ; Wee Shiong LIM
Annals of Geriatric Medicine and Research 2025;29(1):138-141
3.Yubi-Wakka Test for Sarcopenia Screening: Influence of Abdominal Obesity on Diagnostic Performance
Melissa Rose Berlin PIODENA-APORTADERA ; Sabrina LAU ; Cai Ning TAN ; Justin CHEW ; Jun Pei LIM ; Noor Hafizah ISMAIL ; Yew Yoong DING ; Wee Shiong LIM
Annals of Geriatric Medicine and Research 2025;29(1):138-141
4.Optimising dementia screening in community-dwelling older adults: A rapid review of brief diagnostic tools in Singapore.
Jun Pei LIM ; Sabrina LAU ; Penny LUN ; Jia Ying TANG ; Edwin Shih-Yen CHAN ; Luming SHI ; Liang GUO ; Yew Yoong DING ; Laura TAY ; Reshma A MERCHANT ; Wee Shiong LIM
Annals of the Academy of Medicine, Singapore 2024;53(12):742-753
INTRODUCTION:
Timely detection of dementia enables early access to dementia-specific care services and interventions. Various stakeholders brought together to refine Singapore's dementia care strategy identified a lack of a standardised cognitive screening tool and the absence of a comparative review of existing tools. We hence conducted a rapid review to evaluate the diagnostic performance of brief cognitive screening tools in identifying possible dementia among community-dwelling older adults in Singapore.
METHOD:
Brief cognitive screening tools were defined as interviews or tests administered in ≤5 minutes. Studies performed in Singapore on older adults ≥60 years, which used locally-validated comparators and reported outcomes of clinician-diagnosed dementia were included. Rapid review methodology was used in study screening and selection. Quality Assessment of Diagnostic Accuracy Studies version 2 tool was used for risk-of-bias assessment. A negative likelihood ratio (LR-) of ≤0.2 was defined a priori as having a moderate effect in shifting post-test probability.
RESULTS:
Fourteen studies were included in qualitative synthesis: 3 studies evaluated self-/informant-based tools only, 4 evaluated performance-based measures only and 7 evaluated combination approaches. Eight-item Informant Interview to Differentiate Aging and Dementia (AD8) was the most studied self-/ informant-based tool. One study found informant AD8 (iAD8) superior to self-rated AD8. Another study found iAD8 superior to Mini-Mental State Examination. Among performance-based measures, Abbreviated Mental Test, Visual Cognitive Assessment Test-Short form version 1 (VCAT-S1), VCAT-S2 and Mini-Cog had LR- <0.2. Minimal improvement of combination approaches compared to iAD8 alone was demonstrated.
CONCLUSION
Our review suggests the limited utility of dementia screening in communities with low dementia prevalence and supports a case-finding approach instead. With a reliable informant, iAD8 alone has sufficient discriminant ability. Further research is needed to specifically assess the diagnostic ability of performance-based tools in community settings.
Humans
;
Singapore
;
Dementia/diagnosis*
;
Aged
;
Independent Living
;
Mass Screening/methods*
;
Middle Aged
;
Aged, 80 and over
5.CPG UPDATE - Practical guide in using insulin degludec/insulin aspart: A multidisciplinary approach in Malaysia
Siew Pheng Chan ; Malik Mumtaz ; Jeyakantha Ratnasingam ; Alexander Tong Boon Tan ; Siang Chin Lim ; Azhari Rosman ; Kok Han Chee ; Soo Kun Lim ; Shiong Shiong Yew ; Barakatun-Nisak Mohd Yusof ; Bik Kui Lau ; Saiful Bahari Kassim ; Mafauzy Mohamed
Malaysian Family Physician 2023;18(All Issues):1-12
Insulin degludec/insulin aspart (IDegAsp) co-formulation provides both basal and mealtime glycaemic control in a single injection. The glucose level-lowering efficacy of IDegAsp is reported to be superior or non-inferior to that of the currently available insulin therapies with a lower rate of overall hypoglycaemia and nocturnal hypoglycaemia. An expert panel from Malaysia aims to provide insights into the utilisation of IDegAsp across a broad range of patients with type 2 diabetes mellitus (i.e. treatment-naïve or insulin-naïve patients or patients receiving treatment intensification from basal-only regimens, premixed insulin and basal–bolus insulin therapy). IDegAsp can be initiated as once-daily dosing for the main meal with the largest carbohydrate content with weekly dose adjustments based on patient response. A lower starting dose is recommended for patients with cardiac or renal comorbidities. Dose intensification with IDegAsp may warrant splitting into twice-daily dosing. IDegAsp twice-daily dosing does not need to be split at a 50:50 ratio but should be adjusted to match the carbohydrate content of meals. The treatment of patients choosing to fast during Ramadan should be switched to IDegAsp early before Ramadan, as a longer duration of titration leads to better glycated haemoglobin level reductions. The pre-Ramadan breakfast/lunch insulin dose can be reduced by 30%–50% and taken during sahur, while the pre-Ramadan dinner dose can be taken without any change during iftar. Education on the main meal concept is important, as carbohydrates are present in almost all meals. Patients should not have a misconception of consuming more carbohydrates while taking IDegAsp.
insulin degludec [Supplementary Concept]
;
Insulin Aspart
;
Glucose
;
Hypoglycaemia
;
Diabetes Mellitus, Type 2


Result Analysis
Print
Save
E-mail